Saturday, 1 June 2013

ASCO: Immune Therapy Durable in Melanoma

CHICAGO (MedPage Today) -- A therapy aimed at reviving the immune response to advanced melanoma generated durable responses in long-term follow-up of an early clinical trial, a researcher said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..

No comments:

Post a Comment